QQQ $ 602.45 $ -1.66 (-0.27 %)
DIA $ 462.75 $ -1.92 (-0.41 %)
SPY $ 665.17 $ -1.70 (-0.25 %)
TLT $ 90.69 $ -0.30 (-0.33 %)
GLD $ 387.52 $ 1.52 (0.39 %)
$ 0.7101
-- x --
-- x --
-- - --
$ 0.17 - $ 2.70
1,453
na
2.26M
$ 0.16
$ 1.63
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 avenue-therapeutics-q2-eps-011-up-from-643-yoy-sales-1404m

Avenue Therapeutics (OTC:ATXI) reported quarterly earnings of $0.11 per share. This is a 101.71 percent increase over losses of...

 venue-therapeutics-files-for-mixed-shelf-of-upto-35m

- SEC Filing

 avenue-therapeutics-q3-eps-192-misses-094-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of...

 avenue-therapeutics-q2-eps-643-misses-105-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(6.43) per share which missed the analyst consensus estimate of...

 avenue-therapeutics-q1-eps-1540-misses-900-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(15.40) per share which missed the analyst consensus estimate o...

 avenue-therapeutics-may-offer-shares-of-common-stock-having-offering-price-of-up-to-39m-from-time-to-time-through-agent

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION